Unique cannabis extract found to be safe, tolerable and with no intoxication

The specific pharmaceutical-grade cannabis medicine is currently used in the UK and Australia for chronic health conditions including pain, autism, epilepsy, anxiety and dementia

Treatment offers hope for about 43% of UK adults suffering from Chronic Pain

Sydney Australia, 14 October 2020 Medicinal cannabis, company, Bod Australia Limited (“Bod”, the “Company”) (ASX: BDA) has undertaken a Phase I trial of the safety, tolerability and pharmacokinetics of cannabidiol (CBD), administered in healthy volunteers across multiple formulations, conducted at the Nucleus Network (Melbourne, Australia).

The study, published today in leading British Journal of Clinical Pharmacology, demonstrates the safety, tolerability and bioavailability of Cannabis sativa – Linnea 315CSE extract (available as MediCabilis™ Cannabis sativa 50) in oil and sublingual wafer formation compared to nabiximols oromucosal spray.

Continue at Mirage News